search
Back to results

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

Primary Purpose

Non-small Cell Lung Cancer

Status
Unknown status
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Selected Vegetable and Herb Mix
Sponsored by
Sun Farm Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Pathological and radiographic documented stage IIIB/IV NSCLC (squamous, adenocarcinoma, bronchioloalveolar, large cell, undifferentiated or not otherwise specified non-small cell carcinoma) diagnosed less than two months prior to randomization. Patients must have ECOG performance status of 0-1 and life expectancy >3 months. Patients must never have been diagnosed with any malignancy other than the current NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the cervix. Patients must be >18 years of age. Patients must demonstrate the ability and willingness to eat solid food and SV/placebo. Patients must demonstrate the ability and willingness to give informed consent. Patients must demonstrate the ability and willingness to follow the study requirements. Exclusion Criteria: Laboratory criteria for exclusion within 14 days prior to randomization. Liver function: bilirubin > 1.5x upper limit of normal (ULN) and SGOT (AST) > 2.5x ULN. Renal function: Serum creatinine >1.5x ULN Bone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3. Hemoglobin <9 gm/dl for males; < 8.5 gm/dl for females. Unexplained temperature > 38.5° C for any 7 consecutive days or chronic diarrhea defined as > 3 stools/day persisting for 15 consecutive days, within the 30 days prior to randomization. Prior chemotherapy within 5 years. Prior radiation to the area of measurable or active tumor. Significant cardiac disease (i.e. uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous year) or serious cardiac arrhythmia requiring medication. Evidence of clinically significant neuropathy (> Grade 1) by physical exam. Patients must not be pregnant or breast-feeding. Female patients of child-bearing potential must have a negative pregnancy test performed within 72 hours prior to randomization. Women of child-bearing potential must agree not to become pregnant while participating in the study. Active acute infection, except for Herpes viruses (cytomegalovirus [CMV], Epstein Barr virus [EBV], herpes zoster virus [HZV], herpes simplex virus 1 [HSV 1]). A serious underlying medical condition other than NSCLC such that life expectancy is less than 2 years. Psychiatric illness that may affect the patient's compliance with the treatment. Current use of illicit drugs, glucocorticoids other than those necessary for concurrent radiotherapy, adrenal failure or septic shock, or other immune-suppressing or immune-modulating drugs. Glucocorticoids for anti-emetic prophylaxis and therapy should only be used as a last resort. A known allergy to one or more components of SV, namely soy beans, mushrooms, mung beans, red dates, scallion, garlic, lentil beans, leek, hawthorn fruit, onions, ginseng, angelica root, Chinese licorice, dandelion root, Senegal root, ginger, olives, sesame seed and parsley.

Sites / Locations

  • Mount Sinai School of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Placebo Comparator

Arm Label

Study 1: Chemotherapy plus SV or Placebo

Study 2: SV vs Placebo without chemotherapy

Arm Description

For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.

For those who have stopped or refuse standard chemotherapy but will receive best supportive care.

Outcomes

Primary Outcome Measures

Survival Time

Secondary Outcome Measures

Tumor response
Quality of Life
Toxicity of SV
Assessed anually at Safety Monitoring Board

Full Information

First Posted
October 27, 2005
Last Updated
October 28, 2011
Sponsor
Sun Farm Corporation
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00246727
Brief Title
Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer
Official Title
Study 1: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Chemotherapy: A Randomized Double Blind Placebo Controlled Study; Study 2: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Best Supportive Care: A Randomized Double Blind Placebo Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2011
Overall Recruitment Status
Unknown status
Study Start Date
December 2005 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sun Farm Corporation
Collaborators
National Center for Complementary and Integrative Health (NCCIH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of these two studies is to test the hypothesis that the daily ingestion of a dietary supplement, Selected Vegetables and Herbs Mix (SV), which consists of non-toxic botanicals containing known anti-cancer and/or immune enhancing components, may prolong the survival time of stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Either SV or placebo will be added to their daily diet in a double-blind randomized fashion, so that there will be 2 chances out of 3 of receiving SV and 1 chance out of 3 of receiving placebo. Study 1: For newly diagnosed patients who will be receiving or have received less than 4 weeks of, a standard chemotherapy regimen. Study 2: For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
Detailed Description
Carcinoma of the lung is the leading cause of cancer related deaths in North America. Non-small Cell Lung Cancer (NSCLC) causes the death of more than 400,000 patients annually in the US and Western Europe. The benefit of conventional therapies, such as chemotherapy and radiotherapy, for unresectable stage IIIB and IV NSCLC patients is small; the generally accepted median survival time of late stage patients has remained 4-6 months in the "Supportive Care" group and 6-9 months in the chemotherapy treatment group; the one-year survival is about 20%. Ideal Treatment for NSCLC: The toxicity of chemotherapy and side-effects of radiotherapy to the quality of life of the patients have been a major issue in cancer treatments. It has been significant enough that many patients choose to forgo standard treatments. Furthermore, the current chemotherapy for advanced NSCLC is quite expensive, about $50,000 to $100,000 per year. Therefore, an ideal treatment for advanced NSCLC patients should meet the following criteria: Prolong patient survival. Minimal toxicity. Improvement in the patient's quality of life. Relatively inexpensive. A phytomix consisting of selected vegetables and herbs appears to meet all these criteria. The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect. The Objectives of the proposed studies are to evaluate the benefits and adverse reactions of adding SV to the daily diet of cancer patients who are willing to undergo the chemotherapy (Study 1) or those who refuse chemotherapy (Study 2).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study 1: Chemotherapy plus SV or Placebo
Arm Type
Placebo Comparator
Arm Description
For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
Arm Title
Study 2: SV vs Placebo without chemotherapy
Arm Type
Placebo Comparator
Arm Description
For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
Intervention Type
Drug
Intervention Name(s)
Selected Vegetable and Herb Mix
Intervention Description
The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
Primary Outcome Measure Information:
Title
Survival Time
Time Frame
Median Survival Time (MST)
Secondary Outcome Measure Information:
Title
Tumor response
Time Frame
After one month of treatment
Title
Quality of Life
Time Frame
For length of study while on active treatment
Title
Toxicity of SV
Description
Assessed anually at Safety Monitoring Board
Time Frame
Annually

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathological and radiographic documented stage IIIB/IV NSCLC (squamous, adenocarcinoma, bronchioloalveolar, large cell, undifferentiated or not otherwise specified non-small cell carcinoma) diagnosed less than two months prior to randomization. Patients must have ECOG performance status of 0-1 and life expectancy >3 months. Patients must never have been diagnosed with any malignancy other than the current NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the cervix. Patients must be >18 years of age. Patients must demonstrate the ability and willingness to eat solid food and SV/placebo. Patients must demonstrate the ability and willingness to give informed consent. Patients must demonstrate the ability and willingness to follow the study requirements. Exclusion Criteria: Laboratory criteria for exclusion within 14 days prior to randomization. Liver function: bilirubin > 1.5x upper limit of normal (ULN) and SGOT (AST) > 2.5x ULN. Renal function: Serum creatinine >1.5x ULN Bone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3. Hemoglobin <9 gm/dl for males; < 8.5 gm/dl for females. Unexplained temperature > 38.5° C for any 7 consecutive days or chronic diarrhea defined as > 3 stools/day persisting for 15 consecutive days, within the 30 days prior to randomization. Prior chemotherapy within 5 years. Prior radiation to the area of measurable or active tumor. Significant cardiac disease (i.e. uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous year) or serious cardiac arrhythmia requiring medication. Evidence of clinically significant neuropathy (> Grade 1) by physical exam. Patients must not be pregnant or breast-feeding. Female patients of child-bearing potential must have a negative pregnancy test performed within 72 hours prior to randomization. Women of child-bearing potential must agree not to become pregnant while participating in the study. Active acute infection, except for Herpes viruses (cytomegalovirus [CMV], Epstein Barr virus [EBV], herpes zoster virus [HZV], herpes simplex virus 1 [HSV 1]). A serious underlying medical condition other than NSCLC such that life expectancy is less than 2 years. Psychiatric illness that may affect the patient's compliance with the treatment. Current use of illicit drugs, glucocorticoids other than those necessary for concurrent radiotherapy, adrenal failure or septic shock, or other immune-suppressing or immune-modulating drugs. Glucocorticoids for anti-emetic prophylaxis and therapy should only be used as a last resort. A known allergy to one or more components of SV, namely soy beans, mushrooms, mung beans, red dates, scallion, garlic, lentil beans, leek, hawthorn fruit, onions, ginseng, angelica root, Chinese licorice, dandelion root, Senegal root, ginger, olives, sesame seed and parsley.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Henry Sacks, MD, Ph.D
Phone
212-241-7856
Email
henry.sacks@mssm.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henry S Sacks, MD, Ph.D
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai School of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henry S Sacks, MD, Ph.D
Phone
212-241-7856
Email
henry.sacks@mssm.edu
First Name & Middle Initial & Last Name & Degree
Henry S Sacks, MD, Ph.D

12. IPD Sharing Statement

Learn more about this trial

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

We'll reach out to this number within 24 hrs